Vincent T. DeVita, Jr., MD, is the Amy and Joseph Perella Professor of Medicine at the Yale Cancer Center and Professor of Epidemiology and Public Health, and was formerly the Director of the Yale Cancer Center from 1993 to 2003. Dr. DeVita has earned international recognition for his accomplishments as a pioneer in the field of oncology. His professional accomplishments include developing a combination chemotherapy program that led to curative chemotherapy for Hodgkin’s disease and diffuse large cell lymphomas and developing the MOPP four-drug combination which increased the cure rate for patients with advanced Hodgkin’s disease from nearly zero to over 70%. Dr. DeVita currently serves on the editorial boards of numerous scientific journals and is the author or co-author of more than 450 scientific articles.
Theodore S. Lawrence, MD, PhD, FASTRO, FASCO, is the Isadore Lampe Professor and Chair of the Department of Radiation Oncology at the University of Michigan, Ann Arbor. He is Immediate Past President of the Radiation Oncology Institute and Immediate Past Chair of the Radiation Sciences and Medicine Working Group of the American Association of Cancer Research (AACR). Dr. Lawrence is an editor of the Cancer Journal, the associate editor of Seminars in Radiation Oncology, a senior editor for Cancer Research, and a scientific editor for Cancer Discovery. He has received numerous awards, has authored more than 300 peer-reviewed publications, and his work has been continuously supported by the National Cancer Institute for over 25 years.
Steven A. Rosenberg, MD, PhD, is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He is a Professor in the Department of Laboratory Medicine at the Karolinska Institute in Stockholm, Sweden. Dr. Rosenberg pioneered the development of immunotherapy that resulted in the first effective immunotherapies for patients with advanced cancer. He also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. In recent work, Dr. Rosenberg established new approaches for the application of immunotherapy to patients with a variety of common solid cancers by targeting the unique mutations present in the patient’s cancer. Dr. Rosenberg has received numerous awards and has published over 1,100 papers in the peer-reviewed literature.